Wed, Jul 30, 2014, 5:38 AM EDT - U.S. Markets open in 3 hrs 52 mins

Recent

% | $
Click the to save as a favorite.

Ampio Pharmaceuticals, Inc. Message Board

  • gsx1272 gsx1272 Aug 4, 2012 2:13 PM Flag

    R&D costs & more

    I wonder which Pharma companies have zero operating costs. I also wonder which clinical stage Pharmas are making profit. Let's try again. Until the clinical trail data is determined the company obviously can't sell product. Ampio's pipeline is strong and the chances of approval is high.

    Let's use this as an example only.

    Pfizer's Viagra currently costs $1400 for 100 pills. That's $14 a pill. 30%-40% of sexual dysfunction cases are related to premature ejaculation in Australia according to an article published 'Australian Family Physician Vol. 32, No. 11, November 2003.' One in 10 men suffer from SD, so let's assume .3 in 10 men suffer from PE. There are 11.12 million males in AU of which about 38.2% are between 22 and 44. That's 4.24 million. About 127,200 suffer from PE of which 10% or 12,720 try to get help. Let's then assume half of the 12,720 are prescribed Zertane, so we now have a potential of 6360 prescriptions. If Zertane costs $700 for 100 pills that's a profit of 4,452,000 in one fill for the 6360. That could easily double to $8.9M per year.

    These are relatively conservative estimates. It involves only one Country which is ranked No. 52 by population.

    I don't see a point in arguing if the stock price will be $2.00 or $20.00. Nobody here can tell the future. Also talking BS about the company or its short and long investors is useless. Talking the company up to exaggerate that the investors will be rich, again, is useless.

    Just my two cents. Best of luck to all.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMPE
6.02-0.06(-0.99%)Jul 29 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.